BIOLASE Announces Record Sales of $1.25 Million at CDA Meeting

Apr 25, 2001, 01:00 ET from BIOLASE Technology, Inc.

    SAN CLEMENTE, Calif., April 25 /PRNewswire/ -- BIOLASE Technology, Inc.
 (Nasdaq:   BLTI), today announced record sales orders at the California Dental
 Association (CDA), closing a total of 32 lasers valued at $1.25 million in two
 and one-half days, an increase of 500% over last year's CDA sales.  The CDA,
 held from April 20-22, is one of two state-wide meetings held in California
 each year.  Most of the orders this year were for BIOLASE's flagship product,
 the Waterlase(TM) hard and soft tissue laser.  Sales also included an increase
 in Twilite(TM) lasers and LazerSmile(TM) Teeth Whitening systems.
     Jeffrey W. Jones, BIOLASE CEO and president, said, "I am excited by the
 very enthusiastic reception of our products by dentists at the CDA.  The only
 regret I have, if I can have one after such an excellent meeting, is that we
 did not have a large enough booth to properly handle all of the people
 interested in our breakthrough products."
     Jones concluded, "With fourth quarter 2000 sales up 105% and first quarter
 2001 sales up 102% over prior year's same quarters, and the continued growth
 of sales as demonstrated at the CDA, we are confident that this is going to be
 an outstanding year for our company.  We continue to strengthen our position
 as the leader in dental lasers."
 
     BIOLASE Technology, Inc. (www.BIOLASE.com), is an advanced medical
 technology company, which possesses and develops advanced dental, cosmetic,
 aesthetic and surgical products, including Waterlase (HydroKinetic(R))
 surgical cutting systems and other advanced laser- and non-laser-based
 products for the professional and consumer markets.  The company's products
 incorporate patented and patent-pending technologies in the pursuit of
 painless surgery.  BIOLASE is the world leader in painless hard- and
 soft-tissue dental laser technology.
 
     The matters discussed in this news release include forward-looking
 statements, which are subject to various risks, uncertainties and other
 factors that could cause actual results to differ materially from the results
 anticipated in such forward-looking statements.  Such risks, uncertainties and
 other factors include, but are not limited to, the effect of actions of third
 parties, including governmental officials, the timely development and
 acceptance of new products, the impact of competitive products and pricing,
 and other risks detailed from time to time in the Company's filings with the
 Securities and Exchange Commission, including the reports on Forms 10-K and
 10-Q.  These forward-looking statements represent the Company's judgment as of
 the date of this release.  The Company disclaims, however, any intent or
 obligation to update these forward-looking statements.
 
     For further information please contact Lori Parks, VP-Editorial, Elisa
 Keys, SVP-Media Relations, or Leighton Foster, Investor Relations, of Porter,
 LeVay & Rose, Inc., 212-564-4700; or Jeffrey W. Jones, President and CEO of
 BIOLASE Technology, Inc., 949-361-1200.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X08365491
 
 

SOURCE BIOLASE Technology, Inc.
    SAN CLEMENTE, Calif., April 25 /PRNewswire/ -- BIOLASE Technology, Inc.
 (Nasdaq:   BLTI), today announced record sales orders at the California Dental
 Association (CDA), closing a total of 32 lasers valued at $1.25 million in two
 and one-half days, an increase of 500% over last year's CDA sales.  The CDA,
 held from April 20-22, is one of two state-wide meetings held in California
 each year.  Most of the orders this year were for BIOLASE's flagship product,
 the Waterlase(TM) hard and soft tissue laser.  Sales also included an increase
 in Twilite(TM) lasers and LazerSmile(TM) Teeth Whitening systems.
     Jeffrey W. Jones, BIOLASE CEO and president, said, "I am excited by the
 very enthusiastic reception of our products by dentists at the CDA.  The only
 regret I have, if I can have one after such an excellent meeting, is that we
 did not have a large enough booth to properly handle all of the people
 interested in our breakthrough products."
     Jones concluded, "With fourth quarter 2000 sales up 105% and first quarter
 2001 sales up 102% over prior year's same quarters, and the continued growth
 of sales as demonstrated at the CDA, we are confident that this is going to be
 an outstanding year for our company.  We continue to strengthen our position
 as the leader in dental lasers."
 
     BIOLASE Technology, Inc. (www.BIOLASE.com), is an advanced medical
 technology company, which possesses and develops advanced dental, cosmetic,
 aesthetic and surgical products, including Waterlase (HydroKinetic(R))
 surgical cutting systems and other advanced laser- and non-laser-based
 products for the professional and consumer markets.  The company's products
 incorporate patented and patent-pending technologies in the pursuit of
 painless surgery.  BIOLASE is the world leader in painless hard- and
 soft-tissue dental laser technology.
 
     The matters discussed in this news release include forward-looking
 statements, which are subject to various risks, uncertainties and other
 factors that could cause actual results to differ materially from the results
 anticipated in such forward-looking statements.  Such risks, uncertainties and
 other factors include, but are not limited to, the effect of actions of third
 parties, including governmental officials, the timely development and
 acceptance of new products, the impact of competitive products and pricing,
 and other risks detailed from time to time in the Company's filings with the
 Securities and Exchange Commission, including the reports on Forms 10-K and
 10-Q.  These forward-looking statements represent the Company's judgment as of
 the date of this release.  The Company disclaims, however, any intent or
 obligation to update these forward-looking statements.
 
     For further information please contact Lori Parks, VP-Editorial, Elisa
 Keys, SVP-Media Relations, or Leighton Foster, Investor Relations, of Porter,
 LeVay & Rose, Inc., 212-564-4700; or Jeffrey W. Jones, President and CEO of
 BIOLASE Technology, Inc., 949-361-1200.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X08365491
 
 SOURCE  BIOLASE Technology, Inc.